The Potential Benefit of Encorafenib Plus Cetuximab With Chemotherapy Compared With Standard of Care in People With Braf V600E-Mutant Metastatic Colorectal Cancer in the Breakwater Study: A Plain Language Summary

Authors

Scott Kopetz
Takayuki Yoshino
Eric Van Cutsem
Cathy Eng
Tae Won Kim
Harpreet Singh Wasan
Jayesh Desai
Fortunato Ciardiello
Rona Yaeger
Timothy S Maughan
Elena Beyzarov
Xiaoxi Zhang
Graham Ferrier
Xiaosong Zhang
Josep Tabernero

Publication Date

6-1-2025

Journal

Future Oncology

DOI

10.1080/14796694.2025.2491290

PMID

40391894

PMCID

PMC12140493

PubMedCentral® Posted Date

5-20-2025

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Recommended Citation

Kopetz, Scott; Yoshino, Takayuki; Van Cutsem, Eric; et al., "The Potential Benefit of Encorafenib Plus Cetuximab With Chemotherapy Compared With Standard of Care in People With Braf V600E-Mutant Metastatic Colorectal Cancer in the Breakwater Study: A Plain Language Summary" (2025). Faculty, Staff and Student Publications. 4621.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4621